Biograph 55

Biotech company developing a novel cancer immunotherapy. The lead program is a bispecific antibody that targets a unique regulatory B-cell (B-reg) population found in solid tumors and has the potential to address the unmet need of cancer patients who do not respond to the current standard of checkpoint.